Merck's Oral PCSK9 Inhibitor Enlicitide Decanoate Slashes LDL-C by 64.6%, Earns FDA Priority Voucher
MRK sits 61% above its 52-week low of $73.31 on light trading volume (0.3× avg).
Summary
Merck announced highly positive Phase 2 results for its investigational oral PCSK9 inhibitor, Enlicitide Decanoate, demonstrating a significant 64.6% reduction in LDL-C from baseline at eight weeks. This performance notably surpassed guideline-recommended oral non-statin therapies when added to background statins. Further bolstering its potential, the FDA selected Enlicitide for a Commissioner's National Priority Voucher in December 2025, signaling regulatory confidence and potential expedited review. This development is a material positive for Merck's pipeline, offering a promising new asset in the large cardiovascular market, which is crucial as the company faces future revenue declines from Keytruda's patent expiration. The safety profile was consistent with previous trials, showing no meaningful differences in adverse events. Investors will now watch for the drug's progression into Phase 3 trials and subsequent regulatory milestones.
At the time of this announcement, MRK was trading at $118.06 on NYSE in the Life Sciences sector, with a market capitalization of approximately $291.9B. The 52-week trading range was $73.31 to $125.14. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.